18 completed, 17 unknown, 10 terminated, 8 recruiting. 35 Phase 1, 29 Phase 2, 6 Phase 3, 4 Not applicable, 1 Early Phase 1.
Follow Cell- and Tissue-Based Therapy: new trials by email Literature Review of Cell- and Tissue-Based Therapy trials Research Report on Cell- and Tissue-Based Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets - Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Phase 2 | Withdrawn | The First Affiliated Hospital of Soochow University | 2026-05-26 | 2026-06-03 | |
| Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia APR-2020 - RPS19 Deficient Diamond-Blackfan Anemia | Phase 1 | Recruiting | Apriligen, Inc. | 4 | 2026-04-16 | 2026-07-21 |
| A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors Cell therapy with bispecific antibodies - Gynecological Solid Tumors | Not applicable | Recruiting | Obstetrics & Gynecology Hospital of Fudan University | 20 | 2025-05-11 | 2025-04-01 |
| Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors Cellular Therapy - Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors, Hematologic Disease | Not applicable | Active not recruiting | Ruijin Hospital | 200 | 2024-11-07 | 2025-02-27 |
| Autologous CAR-T Cells Targeting B7-H3 in PDAC iC9-CAR.B7-H3 T cell infusion - Pancreas Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 27 | 2024-07-18 | 2026-06-08 |
| A Clinical Study to Evaluate CUD005 Injection in Patients with Liver Cirrhosis Cell therapy - Cirrhosis Liver | Phase 1 | Enrolling by invitation | Anhui Provincial Hospital | 9 | 2024-06-21 | 2024-11-04 |
| GPC3/Mesothelin-CAR-γδT Cells Against Cancers Cell therapy for solid tumors - Pancreas Cancer, Lung Cancer | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 30 | 2024-05-10 | 2024-06-26 |
| Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC Cyclophosphamide, Fludarabine, Cell Therapy - Head and Neck Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 33 | 2024-04-05 | 2026-09-16 |
| A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma AZD5851 - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 94 | 2023-12-14 | 2026-08-19 |
| To Evaluate the Clinical Study of CUD005 Injection in Patients With Cirrhosis Cell therapy - Cirrhosis, Liver | Phase 1 | Unknown | Anhui Provincial Hospital | 9 | 2023-08-09 | 2024-03-06 |
| Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma Selinexor, Flu, CTX - Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 20 | 2022-02-10 | 2026-06-02 |
| Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation Cell Therapy - Intestinal Transplantation | Phase 1 | Recruiting | Columbia University | 6 | 2021-10-22 | 2026-04-01 |
| A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS) ALLOCETRA-OTS, Placebo - Covid19 | Phase 2 | Terminated | Enlivex Therapeutics Ltd. | 12 | 2021-09-01 | 2024-03-13 |
| Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy Mesenchymal Stromal Cell (MSC) injections - Pelvic Radiation Therapy, Radiation-induced Hemorrhagic Cystitis | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 12 | 2021-04-14 | 2021-08-03 |
| Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease Cellular Therapy, Ruxolitinib - Hematopoietic and Lymphoid Cell Neoplasm, Steroid Refractory Graft Versus Host Disease | Early Phase 1 | Recruiting | M.D. Anderson Cancer Center | 24 | 2021-02-17 | 2026-09-23 |
| Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis Cellular therapy with EBV specific autologous CTL infusion - Multiple Sclerosis | Phase 1 | Recruiting | Nantes University Hospital | 7 | 2021-01-26 | 2025-02-19 |
| Open-label Phase I Study for PEP or Treatment of HS-ARS PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS) Cell therapy - Ionizing Radiation Exposure | Phase 1 | Unknown | Pluristem Ltd. | 27 | 2021-01-01 | 2020-07-28 |
| Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients. Cellavita-HD - Huntington Disease | Phase 2 / Phase 3 | Unknown | Azidus Brasil | 35 | 2020-02-10 | 2022-10-28 |
| A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation FCR001 - Transplanted Organ Rejection | Phase 3 | Terminated | Talaris Therapeutics Inc. | 15 | 2019-10-25 | 2023-03-03 |
| Mesenchymal Stem Cells (MSCs) - Like Cell Transplantation in Women With Primary Ovarian Insufficiency Cell therapy - Primary Ovarian Insufficiency | Phase 1 | Unknown | Chinese Academy of Sciences | 28 | 2019-04-03 | 2021-08-05 |
Showing 20 of 63. Sign in to see all of them.
Myocardial Ischemia (4) · Huntington Disease (3) · Neoplasms (3) · Chronic Limb-Threatening Ischemia (2) · Coronary Artery Disease (2) · Diabetes Mellitus (2) · Dyspnea (2) · Fibrosis (2) · Hearing Loss, Sensorineural (2) · Hematologic Neoplasms (2) · Liver Neoplasms (2) · Lung Diseases, Interstitial (2) · Lymphoma, B-Cell (2) · Pancreatic Neoplasms (2) · Pulmonary Disease, Chronic Obstructive (2)
Assistance Publique - Hôpitaux de Paris (4) · Azidus Brasil (3) · Anhui Provincial Hospital (2) · General Hospital of Chinese Armed Police Forces (2) · Hadassah Medical Organization (2) · James Baumgartner, MD (2) · Jonsson Comprehensive Cancer Center (2) · Lung Institute (2) · Ministry of Health, Brazil (2) · Royan Institute (2) · The First Affiliated Hospital of Soochow University (2) · UNC Lineberger Comprehensive Cancer Center (2) · Air Force Military Medical University, China (1) · Amit N. Patel MD MS (1) · Apriligen, Inc. (1)
United States (17) · China (11) · France (9) · Brazil (6) · Israel (4) · Iran (3) · Italy (3) · Spain (2) · Switzerland (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Colombia (1) · Egypt (1) · Germany (1)
Depei Wu, M.D (2) · James Baumgartner, MD (2) · Joyce Macedo da Silva, MD (2) · Shimon Slavin, MD (2) · Amir Ali Hamidieh, MD (1) · Amit N. Patel, MD, MS (1) · Andrew Goldberg, MBBS MD FRCSI FRCS(Tr&Orth) (1) · Ashwin Somasundaram, MD (1) · Attilio Odero, Professor (1) · Bojan Vrtovec, MD, PhD (1) · Carlos Eduardo Rochitte, MD, PhD (1) · Claudia L Sossa-Melo, MD (1) · Daniel Lammertse, M.D. (1)
PMID 16308009, PMID 20364383, PMID 21148423, PMID 21986637, PMID 22040109, PMID 22525310, PMID 24105925, PMID 25700037, PMID 25834975, PMID 25974235, PMID 26217065, PMID 26439886, PMID 26526721, PMID 26895633, PMID 27068030, PMID 27246524, PMID 28753830, PMID 29764889, PMID 35626701, PMID 35775390, PMID 36824456, PMID 37626416, PMID 40593578, PMID 40770775, PMID 41188963, PMID 42265522
2014 (1), P01CA148600 (1), R01CA296807 (1)